Okazaki Medical Clinic, Ukyoku, Kyoto, Japan
Received Date: 28 November 2017; Accepted Date: 06 December 2017; Published Date: 13 December 2017
Citation: Okazaki K (2017) A Case of Tongue Cancer Successfully Treated With 4-Hydroxybenzaldehyde after A Surgical Operation. Res J Oncol. Vol. 1 No. 1: 9.
Copyright: © 2017 Okazaki K. This is an open-access article distributed under the terms of the creative Commons attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Leukemia; Lymphomas; 4-hydroxybenzaldehyde
Mutsuyuki Kochi in 1985, [1,2] reported a unique anti-tumor agent (4-Hydroxybenzaldehyde) after attaining Japanese patent in 1969. Based on his patent report, 4- Hydroxybenzaldehyde is one of the best anti-tumor agent with non-aspect outcomes. In my point of view developed cancers can be treated more efficiently by using 4- Hydroxybenzaldehyde in quantitatively sufficiently to prevent carcinogenesis. According to my observation you should start giving 4-Hydroxybenzaldehyde to the patient who are suffering with cancer in a small dose of the stuff due to the fact, the patient may additionally be afflicted by a severe hemorrhage of the tumor due to excessive necrosis, other type of cancers like leukemia and lymphomas can be handled greater effortlessly due to the fact these tumors don't have any blood vessels. Therefore, the ones who've those illnesses can get hold of extensively large dose of the stuff.
A 72-year-old man (T.I.) visited the author’s clinic on November 25, 2011. He said that he had undergone a surgical operation on the left side of his tongue on October 7, 2011 extirpating 1/3 of his tongue under diagnosis of tongue cancer. He started taking orally 33 ml of 5 mg/ml aqueous solution of 4-Hydroxybenzaldehyde every 10 days on November 26, 2011. He raised the amount of the oral uptake of the same solution every 10 days to 44ml on November 10, 2012. He raised it to 66 ml on May 21, 2013. He raised it to 100 ml on November 12, 2013. He raised it to 150 ml on February 4, 2014. He raised it to 200 ml on July 12, 2014. He started taking orally every day 14ml of the same solution on September 17, 2015. He raised the amount to 40 ml every day on October 17, 2015. He raised the amount to 50 ml every day on January 9, 2016. He raised the amount to 67 ml on April 29, 2017. He currently keeps taking 67 ml of the same solution and shows no sign of recurrence of the disease. He can talk quite normally.
A 37-year-old woman (Y.N.) visited the author’s clinic on November 25, 2011. She said that she had been diagnosed to have a mamma-cancer of Stage I on her left breast in September of 2011 and that she had undergone a surgical operation extirpating the tumor on October 11, 2011. According to her, there was no lymphoid infiltration. She started taking orally 17 ml of 5 mg/ml aqueous solution of 4- Hydroxybenzaldehyde every 10 days on November 25, 2011. She raised the amount of the oral uptake of the same solution every 10 days to 22ml on July 10, 2012. She raised the amount of the oral uptake of the same solution every 10 days to 33 ml on October 16, 2012. She raised the amount of the oral uptake of the same solution every 10 days to 44 ml on January 8, 2013. She raised the amount of the oral uptake of the same solution every 10 days to 67 ml on April 9, 2013. She raised the amount of the oral uptake of the same solution every 10 days to 100 ml on July 9, 2013. Results of her blood-tests of the mamma cancer-specific tumor-marker; CA15-3, performed on March 11, 2013, October 2, 2013, January 16, 2014, April 7, 2014, July 24, 2014, February 12, 2015, September 3, 2015, December 3, 2015, March 7, 2016, July 4, 2016, and March 21, 2017 were 8 U/ml (Normal limit: 30 U/ml), 7 U/ml, 8 U/ml, 6 U/ml, 11 U/ml, 8 U/ml, 7 U/ml, 10 U/ml, 9 U/ml, 8 U/ml and 8 U/ml, respectively. She currently orally takes 100 ml of 5 mg/ml aqueous solution of 4-Hydroxybenzaldehyde every 10 days and is enjoying a healthy life.
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : February 16, 2019